Skip to content

Efficacy and Safety of Vitamin A Treatment for Children With Sepsis

Efficacy and Safety of Vitamin A Treatment for Children With Sepsis: a Randomized Placebo-controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04127968
Enrollment
450
Registered
2019-10-16
Start date
2022-11-01
Completion date
2024-05-31
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric, Sepsis, Vitamin A Deficiency

Brief summary

The prevalence of vitamin A deficiency was found high in children with sepsis. Whether those patients will benefit from the vitamin A supplementation is unknown.

Detailed description

It was reported that the prevalence of vitamin A deficiency was highly as 58% in critically ill children with sepsis. However, whether those patients will benefit from the vitamin A supplementation is unknown. We design an randomized, double-blind, placebo-controlled, multi-center trial to investigate the effect of vitamin A supplementation on the outcome of critically ill children with sepsis.

Interventions

DRUGVitamin A

Children in intervention group will receive 50,000 IU vitamin A after being randomized.

DRUGOil

Children in control group will receive equal volume of oil.

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
0 Months to 192 Months
Healthy volunteers
No

Inclusion criteria

1. age \< 18 years, 2. Expected to stay in the ICU for 48 hours or more, 3. Vitamin A deficiency (VA \< 0.2 mg/L)

Exclusion criteria

1. Severely impaired gastrointestinal function 2. Premature infants and low birth weight (LBW) infants 3. Condition of underlying organ dysfunction 4. Having received chemotherapy or radiotherapy 5. Hematological malignancies 6. Primary or acquired immunodeficiency

Design outcomes

Primary

MeasureTime frameDescription
length of hospital stay2 yearsThe length of hospital stay will be measured by days

Secondary

MeasureTime frameDescription
hospital mortality2 yearsHospital mortality will be record as ratio

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026